Why the study?
European guidelines recommend RAAS inhibitor and CCB or diuretic FDCs as first-line therapy, and adherence is critical for cardiovascular risk reduction, but one-year persistence with ACEI/CCB FDCs required assessment.
Does the specific type of ACEI/CCB fixed-dose combination affect one-year medication persistence in hypertensive patients?
Does the specific type of ACEI/CCB fixed-dose combination affect one-year medication persistence in hypertensive patients?
Among hypertensive patients starting ACEI/CCB fixed-dose combinations, ramipril/amlodipine is associated with the highest one-year persistence compared to other combinations.
No takes yet. Share an insight, caveat, or question.
Simonyi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: